High-dose chemotherapy and autologous stem cell transplantation for nodular lymphocyte-predominant hodgkin lymphoma

Biology of Blood and Marrow Transplantation

Volumn 19, Issue 6, 2013, Pages 991-994

  Karuturi, Meghan ^a   Hosing, Chitra ^a   Fanale, Michelle ^a   Medeiros, L Jeffrey ^a   Alousi, Amin M ^a   de Lima, Marcos J ^a   Qazilbash, Muzaffar H ^a   Kebriaei, Partow ^a   Younes, Anas ^a   Khouri, Issa ^a   Andersson, Borje S ^a   Champlin, Richard ^a   Anderlini, Paolo ^a   Popat, Uday ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Autologous stem cell transplantation; Chemosensitive; Hodgkin Lymphoma; Nodular lymphocyte predominant Hodgkin lymphoma; Relapse

Indexed keywords

ANTINEOPLASTIC AGENT; BUSULFAN; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; IBRITUMOMAB TIUXETAN; MELPHALAN; MITOXANTRONE; RITUXIMAB; THIOTEPA;

ADOLESCENT; ADULT; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; DRUG MEGADOSE; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; MALE; NODULAR LYMPHOCYTE PREDOMINANT HODGKIN LYMPHOMA; OVERALL SURVIVAL; RELAPSE; TREATMENT DURATION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMANS; MALE; MIDDLE AGED; RECURRENCE; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TRANSPLANTATION, AUTOLOGOUS;

EID: 84877912785     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2013.03.008     Document Type: Article

References (13)

1. Lee A.I., LaCasce A.S. Nodular lymphocyte predominant Hodgkin lymphoma. Oncologist 2009, 14:739-751.
2. Nogova L, Rudiger T, Engert A. Biology, clinical course and management of nodular lymphocyte-predominant hodgkin lymphoma. Hematology 2006; Am Soc Hematol Educ Program:266-272.
3. Schulz H., Rehwald U., Morschhauser F., et al. Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long term results of a phase 2 trial by the GHSG. Blood 2008, 111:109-111.
4. Eichenauer D.A., Fuchs M., Pluetschow A., et al. Phase 2 study of rituximab in newly diagnosed stage IA nodular LP-HL: a report from the GHSG. Blood 2011, 118:4363-4365.
5. Linch D.C., Goldstone A.H., McMillan A., et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of BNLI randomized trial. Lancet 1993, 341:1051-1054.
6. Camp E., Swerdlow S.H., Harris H.L., et al. The 2008 WHO Classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood 2011, 117:5019-5032.
7. Cheson B.O., Horning S.J., Coiffer B., et al. Report of an international workshop to standardize response criteria for non-Hodgkins lymphoma. J Clin Oncol 1999, 17:1244-1253.
8. Crump M. Management of Hodgkin lymphoma in relapse after autologous stem cell transplant. Hematology [Abstract] Am Soc Hematol Educ Program 2008, 326-333.
9. Schmitz N., Haverkamp H., Josting A., et al. Long term follow up in relapsed Hodgkin's disease: updated results of HD-R1 study comparing conventional chemotherapy (cCT) to high-dose chemotherapy (HDCT) with autologous hematopoietic stem cell transplantation (ASCT) of the German Hodgkin Study Group (GHSG) and the Working Party Lymphoma of the European Group of Blood and Marrow Transplantation (EBMT) [ASCO abstract 6508]. J Clin Oncol 2005, 23:562s.
10. Bartlett N.L. Therapies for relapsed Hodgkin lymphoma: transplant and non-transplant approaches including immunotherapy. Hematology [Abstract] Am Soc Hematol Educ Program 2005, 245-251.
11. Jackson C., Sirohi B., Cunningham D., et al. Lymphocyte-predominant Hodgkin lymphoma-clinical features and treatment outcomes from a 30-year experience. Ann Oncol 2010, 21:2061-2068.
12. Biasoli I., Stamatoullas A., Meignin V., et al. Nodular, lymphocyte-predominant Hodgkin lymphoma: a long-term study and analysis of transformation to diffuse large B-cell lymphoma in a cohort of 164 patients from the Adult Lymphoma Study Group. Cancer 2010, 116:631-639.
13. Bierman P., Naushad H., Loberiza F., et al. High-dose chemotherapy followed by autologous hematopoietic stem cell transplantation (AHSCT) for lymphocyte predominant Hodgkin's disease [American Society Hematology abstract 3061]. Blood 2006, 108(11):1a-1062a.